Suppr超能文献

不同蛋白尿水平的IgA肾病的长期肾脏预后

Long-term renal outcomes of IgA nephropathy presenting with different levels of proteinuria.

作者信息

Ai Zhen, Zhou Qian, Huang Fengxian, Yang Qiongqiong, Yu Xueqing

出版信息

Clin Nephrol. 2020 Dec;94(6):290-296. doi: 10.5414/CN110192.

Abstract

AIMS

Proteinuria is a strong prognostic factor in IgA nephropathy (IgAN). However, the risk threshold of proteinuria for kidney disease progression remains in debate. This study aimed to evaluate the risk of different levels of proteinuria on renal outcomes in Chinese patients with IgAN.

MATERIALS AND METHODS

Patients with biopsy-proven primary IgAN were recruited and divided into four groups based on their proteinuria levels: ≤ 0.30 g/d, 0.31 - 0.50 g/d, 0.51 - 1.00 g/d, and > 1.00 g/d. The primary outcomes were composed by doubling of baseline serum creatinine (Scr) and end-stage renal disease (ESRD, defined as eGFR < 15 mL/min/1.73m, initiation of dialysis or transplantation).

RESULTS

A total of 921 IgAN patients were enrolled in this study. During a median follow-up duration of 48 (34 - 62) months, higher risks of doubling of baseline Scr developed in patients with proteinuria 0.31 - 0.50 g/d (HR = 2.87, p = 0.04), 0.51 - 1.00 g/d (HR = 4.26, p = 0.002), and > 1.00 g/d (HR = 14.56, p < 0.001), while increased risks for ESRD were observed in patients with proteinuria 0.51 - 1.00 g/d (HR = 3.00, p = 0.02) and > 1.00 g/d (HR = 13.03, p < 0.001) in unadjusted Cox regression models. After adjusted for potential confounders, proteinuria 0.31 - 0.50 g/d (HR = 3.70, p = 0.04), 0.51 - 1.00 g/d (HR = 3.67, p = 0.02), and > 1.00 g/d (HR = 8.20, p < 0.001) remained to be significantly associated with higher risks of doubling of Scr, while only those with proteinuria > 1.00 g/d (HR = 6.04, p = 0.001) exhibited a markedly increased risk of ESRD.

CONCLUSION

Patients with proteinuria levels > 0.30 g/d already have a higher risk of doubling of baseline Scr, suggesting the necessity of early intervention in patients presenting with minimal proteinuria.

摘要

目的

蛋白尿是IgA肾病(IgAN)的一个强有力的预后因素。然而,蛋白尿对于肾脏疾病进展的风险阈值仍存在争议。本研究旨在评估不同水平蛋白尿对中国IgAN患者肾脏结局的风险。

材料与方法

招募经活检证实的原发性IgAN患者,并根据蛋白尿水平分为四组:≤0.30g/d、0.31 - 0.50g/d、0.51 - 1.00g/d和>1.00g/d。主要结局包括基线血清肌酐(Scr)翻倍和终末期肾病(ESRD,定义为估算肾小球滤过率<15mL/min/1.73m²、开始透析或移植)。

结果

本研究共纳入921例IgAN患者。在中位随访时间48(34 - 62)个月期间,未调整的Cox回归模型显示,蛋白尿水平为0.31 - 0.50g/d(HR = 2.87,p = 0.04)、0.51 - 1.00g/d(HR = 4.26,p = 0.002)和>1.00g/d(HR = 14.56,p < 0.001)的患者基线Scr翻倍风险更高,而蛋白尿水平为0.51 - 1.00g/d(HR = 3.00,p = 0.02)和>1.00g/d(HR = 13.03,p < 0.001)的患者ESRD风险增加。在调整潜在混杂因素后,蛋白尿水平为0.31 - 0.50g/d(HR = 3.70,p = 0.04)、0.51 - 1.00g/d(HR = 3.67,p = 0.02)和>1.00g/d(HR = 8.20,p < 0.001)仍与Scr翻倍的较高风险显著相关,而只有蛋白尿>1.00g/d(HR = 6.04,p = 0.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验